Trans Tasman Commercialisation Fund

Active

Updated: Apr 1, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 4, 2013	Heart Metabolics	$4.0M Series A	—	AshHill Investments, Michael Bettess
Aug 10, 2010	Pathway Therapeutics	$4.5M Series A Extension	CM Capital, GBS Venture Partners	Breast Cancer Research Trust, New Zealand Growth Capital Partners

Total Raised

N/A

Valuation

N/A